MedPath

PIO Laser Sclerectomy IOP SLT Sclerectomy

Not Applicable
Completed
Conditions
Primary Open-Angle Glaucoma
Interventions
Procedure: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
Registration Number
NCT01798732
Lead Sponsor
University Hospital, Grenoble
Brief Summary

The main objective of this study is to characterize the changes in IOP over 24 hours after selective trabeculoplasty SLT (before and 1 and 6 months after treatment, decreased IOP, type of rhythm, mesor, acrophase, amplitude). The secondary objective is to evaluate changes in ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after selective laser trabeculoplasty.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  • Primary Open-Angle Glaucoma
  • IOP more than 21 mmHg
  • Progression under maximal medical therapy
  • aged more than 18 years
Exclusion Criteria
  • Pregnant woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Selective laser trabeculoplasty (Tango Laser, Ellex)Selective Laser Trabeculoplasty (Tango Laser, Ellex)Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
Primary Outcome Measures
NameTimeMethod
IOP change over 24 hours after selective trabeculoplasty SLT according to chronobiological data (decrease of IOP; type of 24h-IOP rhythm and 24h-PPm rhythm: MESOR, acrophase, bathyphase, amplitude and modeling)Baseline and 6 months
Secondary Outcome Measures
NameTimeMethod
Changes in the rate of ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after SLT.Baseline and 6 months

* To find predictive factors 1 month before efficacy of the treatment (after 6 month). Efficacy is defined by a mean IOP decrease, at least 30%, with a smoothed pressure-peaks (decrease at least 40% of pressure changes)

* To characterize changes of ocular blood flow parameters (optic nerve head; Volume, Velocity and Flow): 20% at least of increase.

Trial Locations

Locations (1)

University Hospital of Grenoble

🇫🇷

Grenoble, France

© Copyright 2025. All Rights Reserved by MedPath